dimethyl-(1-methyl-cyclohexyl)-amine | 53635-21-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: dimethyl-(1-methyl-cyclohexyl)-amine
• 英文别名: Dimethyl-(1-methyl-cyclohexyl)-amin；1-Dimethylamino-1-methyl-cyclohexan；1-Methylcyclohexyl-dimethylamin；N,N,1-trimethylcyclohexan-1-amine
• CAS: 53635-21-5
• 化学式: C₉H₁₉N
• 分子量: 141.257
• InChiKey: GBVCMCDVQPHZGE-UHFFFAOYSA-N

物化性质

• 沸点：
  66 °C(Press: 20 Torr)
• 密度：
  0.85±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  dimethyl-(1-methyl-cyclohexyl)-amine 在 双氧水 作用下， 生成 dimethyl-(1-methyl-cyclohexyl)-amine oxide
  参考文献：
  名称：

  Reactions of Amines. II. Degradation via Tertiary Amine Oxides¹

  摘要：

  DOI：

  10.1021/ja01569a042
• 作为产物：
  描述：

  甲基环己烷 在 甲醇 、 aluminum(III) nitrate nonahydrate 、 水 、 镍 、 溶剂黄146 作用下， 75.0~140.0 ℃ 、9.81 MPa 条件下， 生成 dimethyl-(1-methyl-cyclohexyl)-amine
  参考文献：
  名称：

  The Synthesis of Some Teritary Carbinamines as Vasopressor Agents

  摘要：

  DOI：

  10.1021/ja01098a033

文献信息

• [EN] NEW PYRROLIDINE-2-CARBOXYLIC ACID DERIVATIVES FOR TREATING PAIN AND PAIN RELATED CONDITIONS<br/>[FR] NOUVEAUX DÉRIVÉS D'ACIDE PYRROLIDINE-2-CARBOXYLIQUE POUR LE TRAITEMENT DE LA DOULEUR ET D'ÉTATS PATHOLOGIQUES ASSOCIÉS À LA DOULEUR
  申请人：ESTEVE PHARMACEUTICALS SA

  公开号：WO2020120606A1

  公开（公告）日：2020-06-18

  The present invention relates to new compounds that show pharmacological activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels or dual activity towards the subunit α2δ of voltage-gated calcium channels (VGCC), especially the α2δ-1 subunit of voltage-gated calcium channels, and the µ-opiod receptor (MOR or mu-opioid). The invention is also related to the process for the preparation of said compounds as well as to compositions comprising them, and to their use as medicaments (formula (I)).

  本发明涉及对电压门控钙通道（VGCC）的亚单位α2δ，特别是对电压门控钙通道的α2δ-1亚单位或对电压门控钙通道（VGCC）的亚单位α2δ表现出药理活性的新化合物，特别是对电压门控钙通道的α2δ-1亚单位，以及与µ-阿片受体（MOR或μ-阿片）具有双重活性。该发明还涉及所述化合物的制备方法，以及包含它们的组合物，以及它们作为药物的用途（公式（I））。
• THIAZOLYL-DIHYDRO-QUINAZOLINE
  申请人：Brandl Trixi

  公开号：US20070244104A1

  公开（公告）日：2007-10-18

  Disclosed are thiazolyl-dihydro-quinazolines of general formula (I) wherein the groups R 1 to R 4 have the meanings given in the claims and specification, the isomers thereof, and processes for preparing these compounds and their use as pharmaceutical compositions.

  揭示了一般式（I）的噻唑基-二氢喹唑啉化合物，其中基团R1至R4具有权利要求和说明书中给定的含义，其异构体，以及制备这些化合物的过程以及它们作为药物组成物的用途。
• ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES
  申请人：Universal Display Corporation

  公开号：US20160072082A1

  公开（公告）日：2016-03-10

  Imidazophenanthridine ligands and metal complexes are provided. The compounds exhibit improved stability through a linking substitution that links a nitrogen bonded carbon of an imidizole ring to a carbon on the adjacent fused aryl ring. The compounds may be used in organic light emitting devices, particularly as emissive dopants, providing devices with improved efficiency, stability, and manufacturing. In particular, the compounds provided herein may be used in blue devices having high efficiency.

  提供了咪唑菲啉配体和金属配合物。这些化合物通过连接取代基展现出改善的稳定性，该连接将咪唑环的氮键合碳与相邻融合芳基环上的碳连接起来。这些化合物可以用于有机发光器件，特别是作为发射杂质，为设备提供改善的效率、稳定性和制造工艺。具体来说，本文提供的化合物可以用于具有高效率的蓝色器件。
• NEW CCR2 RECEPTOR ANTAGONISTS AND USES THEREOF
  申请人：Ebel Heiner

  公开号：US20120004252A1

  公开（公告）日：2012-01-05

  The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonary diseases like asthma and COPD.

  本发明涉及用于治疗疾病和疾病的新型CCR2（CC趋化因子受体2）拮抗剂及其用途，特别是用于治疗哮喘和慢性阻塞性肺病等肺部疾病的药物。
• Synthesis of molecular sieves having the chabazite framework type and their use in the conversion of oxygenates to olefins
  申请人：Cao Guang

  公开号：US20070043249A1

  公开（公告）日：2007-02-22

  The synthesis of a crystalline aluminophosphate or silicoaluminophosphate molecular sieve having a chabazite-type framework type is conducted in the presence of an organic directing agent having the formula (I) [R 1 R 2 R 3 N—R 4 ] + X − (I) wherein R 1 , R 2 and R 3 are independently selected from the group consisting of alkyl groups having from 1 to 3 carbon atoms and hydroxyalkyl groups having from 1 to 3 carbon atoms; R 4 is selected from the group consisting of 4- to 8-membered cycloalkyl groups, optionally substituted by 1 to 3 alkyl groups having from 1 to 3 carbon atoms; 4- to 8-membered heterocyclic groups having from 1 to 3 heteroatoms, said heterocyclic groups being optionally substituted by 1 to 3 alkyl groups having from 1 to 3 carbon atoms and the heteroatoms in said heterocyclic groups being selected from the group consisting of O, N, and S; and aromatic groups optionally substituted by 1 to 3 alkyl groups, said alkyl groups having from 1 to 3 carbon atoms; and X − is an anion.

  在有机引导剂的存在下，以具有方解石型骨架类型的结晶铝磷酸盐或硅铝磷酸盐分子筛的合成在以下化学式（I）[R1R2R3N—R4]+X−(I)中进行，其中R1、R2和R3分别选自由1至3个碳原子的烷基基团和1至3个碳原子的羟基烷基基团组成的群；R4选自由1至3个碳原子的烷基基团和1至3个碳原子的羟基烷基基团组成的群；R4选自由4至8个成员的环烷基基团，可选地由1至3个碳原子的烷基基团取代；由1至3个杂原子组成的4至8个成员的杂环基团，该杂环基团可选地由1至3个碳原子的烷基基团取代，且该杂环基团中的杂原子选自由O、N和S组成的群；和可选地由1至3个碳原子的烷基基团取代的芳香基团；X−是阴离子。